Review top news and interview highlights from the week ending October 21, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
KYV-101 was developed using the construct Kyverna licensed from the NIH in January 2022.
Pam Gavin, executive vice president of NORD, discussed actions the organization is taking to further improve access.
The therapy is currently being evaluated in the phase 1/2 ARYA-1, ARYA-2, and ARYA-3 studies in adults and children.
The executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.
In a rodent model, durable auditory brainstem responses to sound were observed after DB-OTO administration.